Cadila Healthcare Ltd (CADI.NS)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
- BRIEF-Glenmark Pharmaceuticals Launches Biosimilar Of Adalimumab In India
- BRIEF-Cadila Healthcare's Zydus Gets Final Nod From U.S. FDA For Clomipramine Hydrochloride Capsules
- BRIEF-Cadila Healthcare Says Zydus Gets U.S.FDA Nod For Drug to Treat Hypertension, Chest Pain
- BRIEF-Cadila Healthcare Says Zydus Got USFDA Nod For Two Drugs
- BRIEF-Cadila Healthcare's Zydus Gets Final Nod From U.S. FDA For Clozapine Tablets